BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37375331)

  • 21. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
    Li Z; Zhang Y; Feng N
    Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
    Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
    Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesoporous Silica Nanoparticles with Large Pores for the Encapsulation and Release of Proteins.
    Tu J; Boyle AL; Friedrich H; Bomans PH; Bussmann J; Sommerdijk NA; Jiskoot W; Kros A
    ACS Appl Mater Interfaces; 2016 Nov; 8(47):32211-32219. PubMed ID: 27933855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fabrication of Chitosan-coated Mesoporous Silica Nanoparticles Bearing Rosuvastatin as a Drug Delivery System.
    Ghahfarokhi MR; Dini G; Movahedi B
    Curr Drug Deliv; 2022; 19(1):64-73. PubMed ID: 34151762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
    Yan Y; Fu J; Wang T; Lu X
    Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer.
    Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of calcium carbonate-liposome dual-film coated mesoporous silica as a delayed drug release system for antitumor therapy.
    Wang Y; Zhao K; Xie L; Li K; Zhang W; Xi Z; Wang X; Xia M; Xu L
    Colloids Surf B Biointerfaces; 2022 Apr; 212():112357. PubMed ID: 35101825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unsaturated nitrogen-rich polymer poly(l-histidine) gated reversibly switchable mesoporous silica nanoparticles using "graft to" strategy for drug controlled release.
    Mu S; Liu Y; Wang T; Zhang J; Jiang D; Yu X; Zhang N
    Acta Biomater; 2017 Nov; 63():150-162. PubMed ID: 28873341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
    Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
    Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: In vivo study.
    Fahmy HM; Fathy MM; Abd-Elbadia RA; Elshemey WM
    Life Sci; 2019 Apr; 222():94-102. PubMed ID: 30826496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical Characterization and Safety Evaluation of Folic Acid-conjugated Mesoporous Silica Nanoparticles Loaded with Rhodojaponin III.
    Yang Q; Zhao C; Yang J; Zhao J; Feng Y; Liu M; Zhang J
    Curr Drug Deliv; 2023; 20(10):1559-1568. PubMed ID: 36366851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles.
    He Q; Zhang J; Chen F; Guo L; Zhu Z; Shi J
    Biomaterials; 2010 Oct; 31(30):7785-96. PubMed ID: 20674009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biotinylated-lipid bilayer coated mesoporous silica nanoparticles for improving the bioavailability and anti-leukaemia activity of Tanshinone IIA.
    Li Z; Zhang Y; Zhang K; Wu Z; Feng N
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):578-587. PubMed ID: 29374971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chitosan-glucuronic acid conjugate coated mesoporous silica nanoparticles: A smart pH-responsive and receptor-targeted system for colorectal cancer therapy.
    Narayan R; Gadag S; Cheruku SP; Raichur AM; Day CM; Garg S; Manandhar S; Pai KSR; Suresh A; Mehta CH; Nayak Y; Kumar N; Nayak UY
    Carbohydr Polym; 2021 Jun; 261():117893. PubMed ID: 33766378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer.
    Li T; Shi S; Goel S; Shen X; Xie X; Chen Z; Zhang H; Li S; Qin X; Yang H; Wu C; Liu Y
    Acta Biomater; 2019 Apr; 89():1-13. PubMed ID: 30797106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The thermal/pH-sensitive drug delivery system encapsulated by PAA based on hollow hybrid nanospheres with two silicon source.
    Zhang K; Zhang Y; Li Y; Iqbal Z; Yu L; Liu J; Wang H; He P
    J Biomater Sci Polym Ed; 2021 Apr; 32(6):695-713. PubMed ID: 33297850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
    Tang F; Li L; Chen D
    Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
    Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
    Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs.
    Zhang Y; Wang J; Bai X; Jiang T; Zhang Q; Wang S
    Mol Pharm; 2012 Mar; 9(3):505-13. PubMed ID: 22217205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.